Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2015 4
2016 7
2017 5
2018 6
2019 4
2020 10
2021 10
2022 11
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
Tan L, Brown C, Mersiades A, Lee CK, John T, Kao S, Newnham G, O'Byrne K, Parakh S, Bray V, Jasas K, Yip S, Wong SQ, Ftouni S, Guinto J, Chandrashekar S, Clarke S, Pavlakis N, Stockler MR, Dawson SJ, Solomon BJ. Tan L, et al. Among authors: parakh s. Nat Commun. 2024 Feb 28;15(1):1823. doi: 10.1038/s41467-024-46008-1. Nat Commun. 2024. PMID: 38418463 Free PMC article. Clinical Trial.
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
Hegi-Johnson F, Rudd SE, Wichmann CW, Akhurst T, Roselt P, Sursock S, Trinh J, John T, Devereux L, Donnelly PS, Hicks RJ, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, MacManus M. Hegi-Johnson F, et al. Among authors: parakh s. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):675-682. doi: 10.1016/j.ijrobp.2023.05.019. Epub 2023 Jul 3. Int J Radiat Oncol Biol Phys. 2023. PMID: 37406824 No abstract available.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC.
Alexander M, Wei J, Parakh S, John T, Kao S, Nagrial A, Bowyer S, Warburton L, Moore M, Hughes BGM, Clay TD, Pavlakis N, Solomon BJ, Itchins M. Alexander M, et al. Among authors: parakh s. JTO Clin Res Rep. 2023 Feb 26;4(4):100490. doi: 10.1016/j.jtocrr.2023.100490. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37077199 Free PMC article.
58 results